Clinical trials for the testing of a new malaria vaccine on human subjects have begun, Inhabitat reports. The vaccine, called the PfSPZ vaccine, was developed by researchers at Sanaria.
In the first human-based trial, six individuals were injected with the PfSPZ vaccine before being subjected to the bite of mosquitoes infected with malaria. All have shown to be fully immune to the disease.
